GlassScriptPhysician profile
Sarah Bradford
NPI 1851617872
$690.36
in general payments reported to CMS, 2019-2025
15 companies · $115 in 2025
The $115 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $99.00 · 2022: $12.33 · 2023: $94.97 · 2024: $369 · 2025: $115.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $464 · Education: $115.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $464.04 |
| Education | $114.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $223.80 | 2021-2025 | Rybrevant |
| Astrazeneca Pharmaceuticals LP | $123.05 | 2023-2024 | Imfinzi, Tagrisso |
| Takeda Pharmaceuticals U.S.A., INC. | $56.43 | 2024 | Ninlaro, Fruzaqla |
| Merck Sharp & Dohme LLC | $49.78 | 2024 | Keytruda, Welireg |
| Lilly USA, LLC | $35.69 | 2024 | Jaypirca, Verzenio |
| Bayer Healthcare Pharmaceuticals INC. | $28.52 | 2024 | |
| Genentech USA, INC. | $24.49 | 2024 | Phesgo, Alecensa, Perjeta |
| Eisai INC. | $24.38 | 2024 | |
| Pharmacosmos Therapeutics INC. | $22.99 | 2024 | Monoferric |
| Karyopharm Therapeutics INC. | $20.49 | 2024 | Xpovio |
| Celgene Corporation | $19.75 | 2024 | Reblozyl |
| Astellas Pharma US INC | $18.09 | 2024 | Xtandi |
| Legend Biotech USA INC. | $15.99 | 2025 | Carvykti |
| Sumitomo Pharma America, INC. | $14.58 | 2024 | Orgovyx |
| Grifols USA, LLC | $12.33 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Bradford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.